- Media and supplements
Stem cells and stem cell-derived cells
- Human stem cell-derived intestinal epithelial cells
- Human embryonic stem cells
- Human induced pluripotent stem cells
- Human stem cell-derived definitive endoderm cells
- Human stem cell-derived beta cells
- Human stem cell-derived hepatocytes
- Human stem cell-derived cardiomyocytes
- Human multipotent mesenchymal progenitor cells
- Human neural stem cells
Pancreatic beta cells derived from human induced pluripotent stem cells
Cellartis hiPS beta cells have been differentiated from our ChiPSC12 and ChiPSC22 lines of human induced pluripotent stem (hiPS) cells, dissociated into a single-cell suspension, and frozen in vials. Each kit contains beta cells, coating substrate, basal media, and a supplement.
Cellartis hiPS beta cells have been differentiated from our ChiPSC12 and ChiPSC22 lines of control human induced pluripotent stem (hiPS) cells, dissociated into a single-cell suspension, and frozen in vials. Each kit contains beta cells, coating substrate, basal media, and a supplement.
Cellartis hiPS cell-derived beta cell kits contain beta cells generated in vitro using a standardized protocol that mimics embryonic development. These cells secrete high amounts of insulin and C-peptide, and they show substantial protein expression of insulin/C-peptide, MAFA, NKX6-1, PDX1, and UCN3. We offer two complete kits, each containing cells that originate from healthy human donors, including one with a diabetes-susceptible HLA type (HLA-A*02:01). The kits are ideal for investigating beta cell function, diabetes/disease modeling, and compound screening for insulin secretion and regulation.
- Beta cells from ChiPSC12 and ChiPSC22 originate from healthy human donors
- Beta cells from ChiPSC22 originate from a donor with a diabetes-susceptible HLA type, HLA-A*02:01 (Marron et al. 2002)
- Beta cells from ChiPSC22 can be used alone or in combination with beta cells from ChiPSC12, which have an alternate HLA type
- Cells show protein expression of insulin/C-peptide, MAFA, NKX6-1, PDX1, and UCN3
- Cells demonstrate insulin and C-peptide secretion
- Cells were derived with a protocol that mimics embryonic development
- Cells provide reproducible and biologically relevant data
The tissues used for the reprogramming of somatic cells into hiPSCs are from donors who have signed informed consent which outlines in detail the purpose of the donation and the procedure for processing of the donated tissue. In order to protect the privacy and the confidentiality of the donors, all identifiers associated with the donors have been removed. The donor consent was obtained for commercial use. The donation did not result in any financial gain for the donors.
- ChiPSC12 was sourced from skin fibroblasts from a healthy 24-year-old European/North African male volunteer (77 kg/177 cm).
- ChiPSC22 was sourced from skin fibroblasts from a healthy 32-year-old European/North African male volunteer (74 kg/179 cm) with a diabetes-susceptible HLA type, HLA-A*02:01.
HLA typification data for each line is shown below.
|Cellartis hiPS Beta Cells (from ChiPSC12) (Cat. # Y10100)||Cellartis hiPS Beta Cells (from ChiPSC22) (Cat. # Y10106)|
|HLA-B*08:01, HLA-B*37:01||HLA-B*07:02, HLA-B*40:01|
|HLA-C*06:02, HLA-C*07:01||HLA-C*03:04, HLA-C*07:02|
|HLA-DRB1*03:01, HLA-DRB1*11:04||HLA-DRB1*13:02, HLA-DRB1*14:01|
|HLA-DQB1*02:01, HLA-DQB1*03:01||HLA-DQB1*05:03, HLA-DQB1*06:04|
|HLA-DPB1*01:01, HLA-DPB1*04:01||HLA-DPB1*03:01, HLA-DPB1*04:01|
- Disease modeling for diabetes
- Compound screening for insulin secretion and regulation
- Beta-cell functionality
- GSIS (glucose-stimulated insulin secretion) analysis
- Incretin response studies
- Autoimmune beta-cell destruction
- Pancreatitis and beta-cell function
- 1 vial (4.8 x 106 viable cells) of Cellartis hiPS beta cells from ChiPSC12 or ChiPSC22
- 11 vials (360 µl/vial) of Cellartis Beta Cell Supplement
- 1 tube (4 ml) of Cellartis Beta Cell Coating
- 1 bottle (160 ml) of Cellartis Beta Cell Basal Medium
- 1 bottle (30 ml) of Cellartis Beta Cell Basal Medium 2
Marron, M. et al. Functional evidence for the mediation of diabetogenic T cell responses by HLA-A2.1 MHC class I molecules through transgenic expression in NOD mice. Proc Nat Acad Sci U. S. A. 99, 13753–8 (2002).
Additional product information
Please see the product's Certificate of Analysis for information about storage conditions, product components, and technical specifications. Please see the Kit Components List to determine kit components. Certificates of Analysis and Kit Components Lists are located under the Documents tab.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2020 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.